tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Inmune Bio Reveals Promising XPro™ Trial Results

Story Highlights
  • INmune Bio will present Phase 2 trial results of XPro™ at an Alzheimer’s conference.
  • The trial showed promising results in a subpopulation, despite not meeting the primary endpoint.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Inmune Bio Reveals Promising XPro™ Trial Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Inmune Bio ( (INMB) ) is now available.

On July 24, 2025, INmune Bio Inc. announced that additional analyses from its Phase 2 MINDFuL trial of XPro™, a novel TNF inhibitor, will be presented at the Alzheimer’s Association International Conference in Toronto. While the primary endpoint was not met, the trial showed promising results in a subpopulation of patients with specific biomarkers, suggesting potential benefits in slowing cognitive decline in early-stage Alzheimer’s disease. The company is seeking a strategic partnership to further develop XPro™.

The most recent analyst rating on (INMB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases. The company has three product platforms, including the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which is in clinical trials for conditions such as Mild Alzheimer’s disease and treatment-resistant depression. Other platforms include the Natural Killer Cell Priming Platform and CORDStrom™, aimed at cancer and chronic inflammation-related diseases.

Average Trading Volume: 2,731,379

Technical Sentiment Signal: Sell

Current Market Cap: $73.91M

For detailed information about INMB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1